BioInvent and Transgene to Present Promising Initial Phase 1/2a Data on Oncolytic Virus, BT-001, at ESMO 2024

LUND, SE / ACCESSWIRE / September 09, 2024 / BioInvent International (STO:BINV)BT-001 monotherapy showed stable disease and injected lesions shrinkage in advanced solid tumor patients.Promising efficacy data in combination with KEYTRUDA …
Jetzt den vollständigen Artikel lesen